120 related articles for article (PubMed ID: 19156626)
1. Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
Hanefeld M; Karasik A; Koehler C; Westermeier T; Chiasson JL
Diab Vasc Dis Res; 2009 Jan; 6(1):32-7. PubMed ID: 19156626
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
3. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Lancet; 2002 Jun; 359(9323):2072-7. PubMed ID: 12086760
[TBL] [Abstract][Full Text] [Related]
4. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
[TBL] [Abstract][Full Text] [Related]
5. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
Hanefeld M; Chiasson JL; Koehler C; Henkel E; Schaper F; Temelkova-Kurktschiev T
Stroke; 2004 May; 35(5):1073-8. PubMed ID: 15073402
[TBL] [Abstract][Full Text] [Related]
6. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.
Chiasson JL
Endocr Pract; 2006; 12 Suppl 1():25-30. PubMed ID: 16627376
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.
Quilici S; Chancellor J; Maclaine G; McGuire A; Andersson D; Chiasson JL
Int J Clin Pract; 2005 Oct; 59(10):1143-52. PubMed ID: 16178980
[TBL] [Abstract][Full Text] [Related]
8. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
10. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
Liebl A
Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
[TBL] [Abstract][Full Text] [Related]
11. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
12. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL
Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
[TBL] [Abstract][Full Text] [Related]
13. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169
[TBL] [Abstract][Full Text] [Related]
14. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
[TBL] [Abstract][Full Text] [Related]
15. Effect of acarbose on vascular disease in patients with abnormal glucose tolerance.
Hanefeld M; Schaper F; Koehler C
Cardiovasc Drugs Ther; 2008 Jun; 22(3):225-31. PubMed ID: 18309462
[TBL] [Abstract][Full Text] [Related]
16. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
Delorme S; Chiasson JL
Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
[TBL] [Abstract][Full Text] [Related]
17. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; De Grauw WJ
Cochrane Database Syst Rev; 2006 Oct; (4):CD005061. PubMed ID: 17054235
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
Tuomilehto J; Lindström J; Hellmich M; Lehmacher W; Westermeier T; Evers T; Brückner A; Peltonen M; Qiao Q; Chiasson JL
Diabetes Res Clin Pract; 2010 Feb; 87(2):267-74. PubMed ID: 20022651
[TBL] [Abstract][Full Text] [Related]
19. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
Holman RR; Bethel MA; Chan JC; Chiasson JL; Doran Z; Ge J; Gerstein H; Huo Y; McMurray JJ; Ryden L; Liyanage W; Schröder S; Tendera M; Theodorakis MJ; Tuomilehto J; Yang W; Hu D; Pan C;
Am Heart J; 2014 Jul; 168(1):23-9.e2. PubMed ID: 24952856
[TBL] [Abstract][Full Text] [Related]
20. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
Leschke M
Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]